RTP Mobile Logo
Oncology Today with Dr Neil Love: Novel Agents and Strategies in AML (Audio Interview)
Released November 2022

Featuring an interview with Dr Eytan Stein. Published November 17, 2022. (Audio Interview)

CE Information and Faculty Disclosures

  • TARGET AUDIENCE
    This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of acute myeloid leukemia.

    LEARNING OBJECTIVES

    • Evaluate the importance of age, performance status and other biologic and disease-related factors in the selection and sequencing of therapy for patients with various presentations of acute myeloid leukemia (AML).
    • Appreciate the FDA approval of venetoclax in combination with azacitidine, decitabine or low-dose cytarabine for patients with newly diagnosed AML not eligible for intensive therapy, and identify individuals for whom this novel agent would be an appropriate treatment.
    • Recognize the rationale for targeting the cell surface marker CD47 in AML, and consider available research findings with and the potential role of novel approaches to therapeutically exploit this antigen.
    • Describe the role of TIM-3 in normal cellular function and cancer pathogenesis, and discern how novel therapies targeting this immune checkpoint receptor may be beneficial in the care of patients with AML.
    • Consider the potential practical benefits of therapy with an oral hypomethylating agent for patients with AML, and evaluate available and emerging data investigating this strategy.
    • Compare and contrast the toxicities associated with novel treatment approaches for patients with AML, and offer supportive management strategies to minimize or ameliorate these side effects.
    • Recall the design of ongoing clinical trials evaluating novel agents and strategies for AML, and counsel appropriate patients about availability and participation.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    CME credit is no longer available for this issue

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component.
    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Presentations Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Eytan M Stein, MD
    Chief, Leukemia Service
    Director, Program for Drug Development in Leukemia
    Associate Attending Physician
    Leukemia Service, Department of Medicine
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Consulting Agreements: AbbVie Inc, Agios Pharmaceuticals Inc, Aptose Biosciences Inc, Astellas, Blueprint Medicines, Bristol-Myers Squibb Company, Calithera Biosciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Foghorn Therapeutics, Genentech, a member of the Roche Group, Genesis Therapeutics, Gilead Sciences Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Kura Oncology, Menarini Group, Neoleukin Therapeutics, Novartis, OnCusp Therapeutics, Ono Pharmaceutical Co Ltd, PinotBio, Servier Pharmaceuticals LLC, Syndax Pharmaceuticals Inc, Syros Pharmaceuticals Inc.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, Genentech, a member of the Roche Group, Kronos Bio Inc, and Taiho Oncology Inc.

    Release date: November 2022
    Expiration date: November 2023

Acknowledge and close

Watch video
(WIFI is recommended for best performance):